Literature DB >> 17324118

Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System.

Carmen Dumaual1, Xin Miao, Thomas M Daly, Carsten Bruckner, Reuben Njau, Dong-Jing Fu, Sandra Close-Kirkwood, Nancy Bauer, Nancy Watanabe, Paul Hardenbol, Richard D Hockett.   

Abstract

The combined effects of multiple polymorphisms in several drug-metabolizing enzyme and transporter genes can contribute to considerable interindividual variation in drug disposition and response. Therefore, it has been of increasing interest to generate scalable, flexible and cost-effective technologies for large-scale genotyping of the drug-metabolizing enzyme and transporter genes. However, the number of drug-metabolizing enzyme and transporter gene variants exceeds the capacity of current technologies to comprehensively assess multiple polymorphisms in a single, multiplexed assay. The Targeted Genotyping System (Affymetrix, CA, USA) provides a solution to this challenge, by combining molecular inversion probe technology with universal microarrays to provide a method that is capable of analyzing thousands of variants in a single reaction, while remaining relatively insensitive to cross-reactivity between reaction components. This review will focus on the Targeted Genotyping System and how this technology was adapted to enable comprehensive analysis of drug-metabolizing enzyme and transporter gene polymorphisms.

Mesh:

Substances:

Year:  2007        PMID: 17324118     DOI: 10.2217/14622416.8.3.293

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  17 in total

Review 1.  Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact.

Authors:  Federico M Goodsaid; Shashi Amur; Jiri Aubrecht; Michael E Burczynski; Kevin Carl; Jennifer Catalano; Rosane Charlab; Sandra Close; Catherine Cornu-Artis; Laurent Essioux; Albert J Fornace; Lois Hinman; Huixiao Hong; Ian Hunt; David Jacobson-Kram; Ansar Jawaid; David Laurie; Lawrence Lesko; Heng-Hong Li; Klaus Lindpaintner; James Mayne; Peter Morrow; Marisa Papaluca-Amati; Timothy W Robison; John Roth; Ina Schuppe-Koistinen; Leming Shi; Olivia Spleiss; Weida Tong; Sharada L Truter; Jacky Vonderscher; Agnes Westelinck; Li Zhang; Issam Zineh
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

2.  Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

Authors:  John F Deeken; Robert W Robey; Suneet Shukla; Kenneth Steadman; Arup R Chakraborty; Balasubramanian Poonkuzhali; Erin G Schuetz; Susan Holbeck; Suresh V Ambudkar; Susan E Bates
Journal:  Mol Pharmacol       Date:  2009-07-24       Impact factor: 4.436

3.  Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records.

Authors:  Matthew T Oetjens; Joshua C Denny; Marylyn D Ritchie; Niloufar B Gillani; Danielle M Richardson; Nicole A Restrepo; Jill M Pulley; Holli H Dilks; Melissa A Basford; Erica Bowton; Dan R Masys; Russell A Wilke; Dan M Roden; Dana C Crawford
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

4.  Concordance of DMET plus genotyping results with those of orthogonal genotyping methods.

Authors:  C A Fernandez; C Smith; W Yang; R Lorier; K R Crews; N Kornegay; J K Hicks; C F Stewart; J D Kawedia; L B Ramsey; C Liu; W E Evans; M V Relling; U Broeckel
Journal:  Clin Pharmacol Ther       Date:  2012-08-08       Impact factor: 6.875

5.  Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.

Authors:  Hersh Sagreiya; Hersh Sagrieya; Caroline Berube; Alice Wen; Ramesh Ramakrishnan; Alain Mir; Amy Hamilton; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-07       Impact factor: 2.089

6.  A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Authors:  J B Dumond; M Vourvahis; N L Rezk; K B Patterson; H-C Tien; N White; S H Jennings; S O Choi; J Li; M J Wagner; N M La-Beck; M Drulak; J P Sabo; M A Castles; T R Macgregor; A D M Kashuba
Journal:  Clin Pharmacol Ther       Date:  2010-02-10       Impact factor: 6.875

7.  Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.

Authors:  Ronan P Kelly; Sandra L Close; Nagy A Farid; Kenneth J Winters; Lei Shen; Fanni Natanegara; Joseph A Jakubowski; Mary Ho; Joseph R Walker; David S Small
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

8.  CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Sara Hamon; Matthew Randesi; Miriam Adelson; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2011-07-25       Impact factor: 4.280

9.  Methods for optimizing statistical analyses in pharmacogenomics research.

Authors:  Stephen D Turner; Dana C Crawford; Marylyn D Ritchie
Journal:  Expert Rev Clin Pharmacol       Date:  2009-09-01       Impact factor: 5.045

10.  Association study between BDNF gene polymorphisms and autism by three-dimensional gel-based microarray.

Authors:  Lu Cheng; Qinyu Ge; Pengfeng Xiao; Beili Sun; Xiaoyan Ke; Yunfei Bai; Zuhong Lu
Journal:  Int J Mol Sci       Date:  2009-06-02       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.